Advanced Filters
noise

Orange, Connecticut Clinical Trials

A listing of Orange, Connecticut clinical trials actively recruiting patient volunteers.

Found 764 clinical trials
C Caitlin E Smith, PhD

Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

The purpose of this research study is to develop and pilot a multiple health behavior change intervention for weight loss and smoking cessation using medication (Naltrexone + Bupropion) and behavior therapy in adults seeking bariatric surgery.

18 - 65 years of age All Phase 1
S Sara Pai, MD, PHD

CUE-101with Pembrolizumab for LA-HPV+HNSCCs

This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A\*0201-positive treatment naive participants with locally advanced, unresectable HPV-16 associated head and neck squamous cell carcinoma (HNSCC).

18 years of age All Phase 2
A Aaron Lazorwitz, MD, PhD

Long Term Evaluation of Scapular-inserted Contraceptive Implants

This study aims to evaluate long-term outcomes when the etonogestrel contraceptive implant is inserted at an alternative site located over the scapular. The study will evaluate the pharmacokinetics (i.e., drug levels) and side effect profiles of participants who have an etonogestrel contraceptive implant inserted at this alternative scapular site over …

18 - 45 years of age Female Phase 2

PoRI Clinical Trial

This randomized clinical trial compares the Portable Rehabilitation Interface (PoRI) device for rehabilitation of hand motor function in post-stroke patients with conventional hand therapy.

18 years of age All Phase N/A
A Ava Reker, B.A.

Transcranial Direct Current Stimulation and Extinction in Obsessive Compulsive Disorder

Obsessive-compulsive disorder (OCD) is associated with substantial impairments in quality of life and is among the most disabling psychiatric disorders. Exposure therapy is among the first-line of treatments for obsessive-compulsive disorder (OCD) . Extinction learning is thought to be a core mechanism of therapeutic exposure. Fear and safety signal learning …

18 - 60 years of age All Phase N/A
C Carl Brown

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

This is a phase II, randomized, double-blinded, placebo-controlled trial designed to evaluate the efficacy of fezolinetant (45 mg a day) vs. placebo in reducing moderate to severe vasomotor symptoms (VMS) in breast cancer survivors on endocrine therapy (tamoxifen, aromatase inhibitors). The trial will proceed in a single stage, and the …

40 - 65 years of age Female Phase 2
C Carolyn K Lauckner, PhD

TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

Ecological momentary interventions (EMI), which use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events, can help to address triggers in real-time. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then …

18 - 35 years of age All Phase N/A
A Ashley Romano, Clinical Research Nurse II, RN

Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.

45 - 85 years of age All Phase 2
N Nicole Trujillo, CRC

OLE Therapy With BE Patients in Home Care Study

The study will examine how the performance of Oscillating Lung Expansion (OLE) therapy affects the respiratory health of patients with Bronchiectasis (BE). The patient will use the BiWaze Clear system for their airway clearance therapy, instead of their previously prescribed therapy. BiWaze Clear is an FDA-cleared respiratory therapy for assisting …

5 years of age All Phase N/A
R Rachel Hart, MA

Prazosin for Alcohol Use Disorder With Withdrawal Symptoms

This is a Phase 2 single site randomized clinical trial (RCT) to be supported by a new NIH-NIAAA grant, R01-AA029113-01, to assess the efficacy of Prazosin (16mg/day) versus Placebo over a 12 week treatment period, followed by a 1- and 3- month assessments post-treatment for individuals with Alcohol Use Disorder …

18 - 70 years of age All Phase 2

Simplify language using AI